Study S003351

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Trial Designed to Evaluate the Efficacy and Safety of CJC-1134-PC Injection Administered Once A Week in Patients With Type 2 Diabetes With Inadequately Controlled Blood Glucose Level After Metformin Monotherapy or Metformin in Combination With Insulin Secretagogues

ClinicalTrials.gov record

Registration

Registration: NCT07057271
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: QUADRUPLE
Status: COMPLETED
Enrollment: 464
Start: 2021-05-27
Primary completion: 2023-02-21
Lead sponsor: Changshan ConjuChem BioPharmaceutical Research and Development (Hebei) Co., Ltd.
Conditions: Type 2 Diabetes Mellitus - Poor Control
Interventions: DRUG:CJC-1134-PC Injection; DRUG:Placebo
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

Change from baseline in HbA1c at the end of double-blind treatment period [Week 25 visit]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.